Oppenheimer reiterated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a report issued on Tuesday.

A number of other research analysts also recently commented on the company. Wells Fargo & Company raised Zimmer Biomet from a market perform rating to an outperform rating in a report on Tuesday. BMO Capital Markets reaffirmed a buy rating and set a $142.00 target price on shares of Zimmer Biomet in a report on Tuesday, December 12th. TheStreet downgraded Zimmer Biomet from a b- rating to a c+ rating in a report on Friday, November 24th. Zacks Investment Research downgraded Zimmer Biomet from a hold rating to a strong sell rating in a report on Monday, November 20th. Finally, Deutsche Bank raised Zimmer Biomet from a hold rating to a buy rating and set a $128.00 target price on the stock in a report on Tuesday, November 14th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Zimmer Biomet has a consensus rating of Buy and an average price target of $133.57.

Zimmer Biomet (NYSE:ZBH) opened at $121.38 on Tuesday. The company has a market capitalization of $23,169.00, a PE ratio of 14.18, a P/E/G ratio of 1.78 and a beta of 1.15. Zimmer Biomet has a 1-year low of $100.87 and a 1-year high of $133.49. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the prior year, the company posted $1.79 EPS. equities analysts forecast that Zimmer Biomet will post 8.03 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend is Thursday, December 28th. Zimmer Biomet’s payout ratio is currently 30.19%.

A number of hedge funds and other institutional investors have recently modified their holdings of ZBH. AXA boosted its position in shares of Zimmer Biomet by 26.3% in the third quarter. AXA now owns 412,845 shares of the medical equipment provider’s stock worth $48,340,000 after buying an additional 85,861 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in shares of Zimmer Biomet in the third quarter worth $140,000. Jana Partners LLC boosted its position in shares of Zimmer Biomet by 16.6% in the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after buying an additional 662,497 shares during the period. Public Employees Retirement System of Ohio boosted its position in shares of Zimmer Biomet by 1.3% in the third quarter. Public Employees Retirement System of Ohio now owns 86,959 shares of the medical equipment provider’s stock worth $10,182,000 after buying an additional 1,131 shares during the period. Finally, Iguana Healthcare Management LLC boosted its position in shares of Zimmer Biomet by 20.0% in the third quarter. Iguana Healthcare Management LLC now owns 30,000 shares of the medical equipment provider’s stock worth $3,513,000 after buying an additional 5,000 shares during the period. 85.92% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Zimmer Biomet (ZBH) Receives Buy Rating from Oppenheimer” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/zimmer-biomet-zbh-receives-buy-rating-from-oppenheimer/1774331.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.